Zenlabs EthicaBOM:530697 +0.93%53 ROA % is 0.01% as of Mar. 2026, which is 99% below its 10-year median of 1.72. GuruFocus rates BOM:530697 with a GF Score™ of 53/100 and a GF Value™ of ₹29.34 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 118 Medical Distribution companies, Zenlabs Ethica ranks worse than 83.05% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Zenlabs Ethica's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹0.0 Mil.
Zenlabs Ethica's average Total Assets over the quarter that ended in Mar. 2026 was ₹372.1 Mil. Therefore, Zenlabs Ethica's annualized ROA % for the quarter that ended in Mar. 2026 was 0.01%.
The historical rank and industry rank for Zenlabs Ethica's ROA % or its related term are showing as below:
BOM:530697'
s ROA % Range Over the Past 10 Years
Min: -4.97 Med: 1.72 Max: 3.9
Current: -4.94
During the past 13 years, Zenlabs Ethica's highest ROA % was 3.90%. The lowest was -4.97%. And the median was 1.72%.
BOM:530697's ROA % is ranked worse than 83.05% of 118
companies
in the Medical Distribution industry
Industry Median: 2.215
vs BOM:530697: -4.94
Zenlabs Ethica (BOM:530697) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Zenlabs Ethica ROA % Related Terms
Zenlabs Ethica ROA % Historical Data
* Premium members only.
The historical data trend for Zenlabs Ethica's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Zenlabs Ethica's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zenlabs Ethica ROA % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Zenlabs Ethica's ROA % distribution charts can be found below:
* The bar in red indicates where Zenlabs Ethica's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Zenlabs Ethica (BOM:530697) has a ROA % of 0.01% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Zenlabs Ethica and its competitors. This is 99% below median its historical median of 1.72. According to the industry distribution chart, Zenlabs Ethica ranks #98 out of 118 companies in the Medical Distribution industry, placing it in the top 83.1%.
Is Zenlabs Ethica's ROA % too high?
Zenlabs Ethica's current ROA % of 0.01% is 99% below median its 10-year median of 1.72. The Medical Distribution industry median ROA % is 2.22. Zenlabs Ethica's value of 0.01% is 99.5% below this industry median. Based on the distribution chart, Zenlabs Ethica ranks #98 out of 118 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Zenlabs Ethica has a GF Score™ of 53/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zenlabs Ethica's ROA % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Zenlabs Ethica ranks #98 out of 118 companies for ROA %. This places Zenlabs Ethica in the lower half of its industry. The industry median ROA % is 2.22. Zenlabs Ethica's value of 0.01% is 99.5% below this benchmark. While the company's 10-year median is 1.72 vs. the industry median of 2.22, Zenlabs Ethica has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Distribution company?
The median ROA % among Medical Distribution companies is 2.22, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zenlabs Ethica's current ROA % of 0.01% is 99.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Zenlabs Ethica and its competitors. For the Medical Distribution industry, the median ROA % is 2.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zenlabs Ethica's current ROA % is 0.01%, which is 99% below median its own 10-year median of 1.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenlabs Ethica stock overvalued right now?
Based on GuruFocus' analysis, Zenlabs Ethica (BOM:530697) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹29.34, compared to a current price of ₹35.80 — trading 22% above its estimated fair value. The current ROA % is 0.01%, which is 99% below median its 10-year median of 1.72 and 99.5% below the Medical Distribution industry median of 2.22. Zenlabs Ethica's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Zenlabs Ethica (BOM:530697), the current ROA % is 0.01% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zenlabs Ethica (BOM:530697) Overvalued in 2026?
Based on GuruFocus' analysis, Zenlabs Ethica stock appears to be overvalued.
The current stock price of ₹35.80 is trading 22% above its estimated GF Value™ of ₹29.34.
GuruFocus considers Zenlabs Ethica to be Modestly Overvalued.
Key valuation signals for BOM:530697:
ROA %: 0.01% (99% below median its 10-year median of 1.72)
GF Value™: ₹29.34 vs. price of ₹35.80 (22% above fair value)
Industry Position: 99.5% below the Medical Distribution median (#98 of 118)
No single metric tells the full story. See the BOM:530697 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zenlabs Ethica Ltd is a pharmaceutical company engaged in the trading of pharmaceutical formulations. It manufactures and markets drugs which include Gastrointestinal disorders, anti-diabetics, anti-hypertensive drugs, anti-infective, soaps, and anti-Bacterial drugs, nutraceuticals, and others. In addition, The company offers more than 600 products across therapeutic segments.
53GF Score
Get the complete analysis for BOM:530697
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530697 has been successfully added to your 
